Study on the Safety and Effectiveness of TORL-1-23 with Chemotherapy Before Surgery in Women with Advanced Ovarian Cancer

Inclusion Criteria

• Women with a good overall health status, as measured by a performance score of 2 or less.
• Diagnosed with epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.
• Cancer must be at an advanced stage (FIGO Stage III or IV).
• Cancer cells must show a specific marker called claudin 6 (CLDN6).
• Must have adequate organ function as determined by medical tests.

Exclusion Criteria

• Have certain types of ovarian cancer, such as clear cell, mucinous, sarcomatous, mixed histology, low-grade/borderline, or non-epithelial.
• Have received any prior systemic treatment for the ovarian cancer being studied.
• Have had previous surgery for the cancer.
• Have had radiation therapy to the abdomen or pelvis.
• Are currently receiving or have recently received chemotherapy, targeted therapy, or immunotherapy for any condition.
• Have active, worsening, or symptomatic cancer spread to the brain.
• Have serious, uncontrolled medical conditions or active infections that make them a poor candidate for the study.
• Are pregnant or breastfeeding.